MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Home・Akciju saraksts・Haemonetics Corp

Haemonetics Corp

Slēgts

SektorsVeselības aprūpe

80.1 -1.27

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

79.71

Max

80.96

Galvenie mērījumi
By Trading Economics
Ienākumi	4.7M 39M
Pārdošana	5.9M 327M
P/E Sektora vidējais	23.547 88.032
EPS	1.27
Peļņas marža	11.819
Darbinieki	3,023
EBITDA	8.8M 87M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+9.2% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.5B 3.9B
Iepriekšējā atvēršanas cena	81.37
Iepriekšējā slēgšanas cena	80.1

Ziņu noskaņojums

By Acuity

50%

157 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

62.51 / N/A Atbalsts un pretestība

Haemonetics Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 31. dec. 22:20 UTC

Galvenie tirgus virzītāji

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

2025. g. 31. dec. 17:31 UTC

Galvenie tirgus virzītāji

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

2025. g. 31. dec. 16:30 UTC

Galvenie tirgus virzītāji

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

2025. g. 31. dec. 15:19 UTC

Galvenie tirgus virzītāji

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

2025. g. 31. dec. 15:17 UTC

Galvenie tirgus virzītāji

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

2025. g. 31. dec. 14:37 UTC

Galvenie tirgus virzītāji

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

2025. g. 31. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 31. dec. 21:13 UTC

Iegādes, apvienošanās, pārņemšana

10 People to Watch in Wealth Management in 2026 -- Barrons.com

2025. g. 31. dec. 20:40 UTC

Tirgus saruna

Dollar Posting Its Worst Year Since 2017 -- Market Talk

2025. g. 31. dec. 20:22 UTC

Tirgus saruna

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

2025. g. 31. dec. 19:50 UTC

Tirgus saruna

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

2025. g. 31. dec. 19:31 UTC

Tirgus saruna

Precious Metals Cap Off Record Runs -- Market Talk

2025. g. 31. dec. 18:50 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 31. dec. 18:50 UTC

Tirgus saruna

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

2025. g. 31. dec. 17:17 UTC

Tirgus saruna

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

2025. g. 31. dec. 17:16 UTC

Galvenie tirgus virzītāji

OwlTing Climbs on Launch of $10M Stock-Buyback Program

2025. g. 31. dec. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 31. dec. 17:00 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

2025. g. 31. dec. 15:57 UTC

Iegādes, apvienošanās, pārņemšana

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

2025. g. 31. dec. 15:54 UTC

Tirgus saruna

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

2025. g. 31. dec. 15:02 UTC

Galvenie tirgus virzītāji

Nike Shares Rise After CEO Hill Buys $1M of Shares

2025. g. 31. dec. 14:40 UTC

Iegādes, apvienošanās, pārņemšana

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

2025. g. 31. dec. 14:20 UTC

Tirgus saruna

Crude Futures On Track to End the Year With Losses -- Market Talk

2025. g. 31. dec. 13:46 UTC

Tirgus saruna

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

2025. g. 31. dec. 13:01 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

2025. g. 31. dec. 11:10 UTC

Tirgus saruna

Copper Remains in Touching Distance of Record Highs -- Market Talk

2025. g. 31. dec. 10:46 UTC

Tirgus saruna

Euro on Track For Strong Annual Performance -- Market Talk

2025. g. 31. dec. 10:25 UTC

Tirgus saruna

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

2025. g. 31. dec. 10:23 UTC

Tirgus saruna

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

2025. g. 31. dec. 09:33 UTC

Tirgus saruna

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Salīdzinājums

Cenas izmaiņa

Haemonetics Corp Prognoze

Cenas mērķis

By TipRanks

9.2% augšup

Prognoze 12 mēnešiem

Vidējais 88.43 USD 9.2%

Augstākais 99 USD

Zemākais 74 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Haemonetics Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Haemonetics Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

62.51 / N/AAtbalsts un pretestība

All events are bullish.

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Noskaņojums

By Acuity

157 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Haemonetics Corp

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.